Las pupilas no solo regulan la cantidad de luz que entra en nuestros ojos. Desde hace décadas, la ciencia ha demostrado que también reaccionan de forma inmediata a nuestras emociones, convirtiéndose en un auténtico “termómetro emocional”. Alegría …
Por qué las pupilas se dilatan con las emociones Read More »
As 2026 begins, a slate of high-stakes clinical readouts—from a pivotal study of Novartis’ cardiovascular candidate pelacarsen to a Phase III test of Eli Lilly’s next-gen Alzheimer’s drug—are poised to reshape therapeutic landscapes.
After a tumultuous year, experts call for stability while anticipating the first fruits of policies intended to expedite approvals for rare disease drugs.
Calls for Leadership Stability and Rare Disease Follow-Through at FDA in 2026 Read More »
The FDA’s announcement that it will phase out in vivo testing requirements for monoclonal antibodies marks a seismic shift. Here’s how industry can adapt.
Addressing the Regulatory Reality of Replacing In Vivo Models in Drug Development Read More »
One way Takeda lives out its values is by striving to ensure that patients are aware of and can access the company’s clinical trials. Two employees from its research and development organization discuss why representation matters and the work their team is doing to benefit patients now and in the future.
Takeda’s Commitment to Trial Representation is Shaping the Future of Clinical Research Read More »
¿Qué es el extracto de semilla de uva? El extracto de semilla de uva es un compuesto natural extraído de las semillas de uva, un subproducto del proceso de vinificación. Este proceso de extracción generalmente implica moler las semillas de uva hasta obtene …
Extracto de semilla de uva: El guardián antioxidante natural Read More »
La inteligencia artificial se ha convertido en una herramienta clave en numerosos sectores, desde la salud y la industria hasta la energía, el transporte y los servicios públicos. Sin embargo, a pesar del interés creciente y de los avances tecnológicos, la adopción …
With a pair of Phase III trial flops, Ultragenyx will explore cost reductions as analysts turn attention to an upcoming Angelman syndrome readout.
Ultragenyx Loses $1B in Market Value as Bone Drug Fails To Reduce Fractures Read More »
The major depressive disorder failure for BHV-7000 is the drug’s second, after Biohaven’s spinocerebellar ataxia treatment troriluzole was rejected by the FDA in November 2025.
Biohaven Notches Another Psychiatric Failure Months After Key FDA Rejection Read More »
While Novartis secured the biggest deal of the fourth quarter, a handful of riveting tales emerged from the bottom of the M&A list, including a zombie buyout and a bidding war. And no, we’re not talking about Metsera.
Big Pharma Dealmakers Joined by Spunky Group of Biotech Buyers in Q4 Read More »
